Skip to main content
NIH funding notice PAR-22-083

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)

Closed on November 6, 2024.

Posted
January 21, 2022
Close date
November 6, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,497,630 in first-year total cost, median $1,748,815.

Most frequent study sections

  1. Molecular Cancer Diagnosis and Classification Study Section[MCDC]1
  2. Special Emphasis Panel[ZRG1 EPH-A (02)]1

Most frequent institutions

  1. UNIVERSITY OF HAWAII AT MANOA1
  2. UT SOUTHWESTERN MEDICAL CENTER1
Competing awards under PAR-22-083 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Non-invasive etiology-adjusted precision liver cancer risk prediction1R01CA292930-01A1HOSHIDA, YUJINUT SOUTHWESTERN MEDICAL CENTER, TX$2,876,456MCDC
2024Cyanobacteria, cyanotoxins, and liver cancer development1U01CA284379-01A1HERNANDEZ, BRENDA YUKARIUNIVERSITY OF HAWAII AT MANOA, HI$621,174ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.